June 16, 2021
1 min read
Save
FDA approves 200 mg prefilled Dupixent pen for at-home use
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
A 200 mg single-dose prefilled pen for Dupixent has been approved by the FDA for at-home use to treat certain patients with atopic dermatitis and asthma, according to a company announcement.
The Dupixent pen (dupilumab, Regeneron) is for patients aged 12 years and older and is expected to be available in the United States in August 2021.
A 300 mg dose of the prefilled pen was previously approved by the FDA in June 2020.